Biotest Aktiengesellschaft Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, sales was EUR 360.8 million compared to EUR 371.4 million a year ago. Net loss was EUR 34.2 million compared to EUR 28.3 million a year ago. Basic loss per share from continuing operations was EUR 0.87 compared to EUR 0.73 a year ago.